Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Melanoma 488Lymphoma, T-Cell, Cutaneous 92Carcinoma, Non-Small-Cell Lung 89Mycosis Fungoides 72Neoplasm Metastasis 71Skin Neoplasms 62Neoplasms 61Sezary Syndrome 60Carcinoma, Renal Cell 60Lymphoma, Non-Hodgkin 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma 53Breast Neoplasms 52Leukemia, Lymphocytic, Chronic, B-Cell 50Lymphoma, Follicular 47Lymphoma, Mantle-Cell 46Lymphoma, B-Cell, Marginal Zone 46Squamous Cell Carcinoma of Head and Neck 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Hodgkin Disease 44Colorectal Neoplasms 43Burkitt Lymphoma 43Lymphoma, Large-Cell, Immunoblastic 41Ovarian Neoplasms 38Multiple Myeloma 35Uveal Melanoma 34Leukemia, Hairy Cell 33Lymphoma, Large-Cell, Anaplastic 32Sarcoma 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 31

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Vaccinia × Dermatologic × Clear all
NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Transgene

Phase 1/2 Terminated
31 enrolled
BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡